Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cyclin-dependent kinase 4 | Starlite/ChEMBL | References |
Homo sapiens | cyclin D1 | References | |
Homo sapiens | cyclin-dependent kinase 3 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 3 | 305 aa | 303 aa | 32.0 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 4 | 303 aa | 312 aa | 29.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.014 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0054 | 0.0239 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0087 | 0.3953 | 0.3876 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0054 | 0.0239 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.014 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.014 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0054 | 0.0239 | 0.0115 |
Leishmania major | p450 reductase, putative | 0.014 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0087 | 0.3953 | 0.3876 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0054 | 0.0239 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0054 | 0.0239 | 0.0115 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0054 | 0.0239 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.014 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.014 | 1 | 1 |
Schistosoma mansoni | diflavin oxidoreductase | 0.007 | 0.2036 | 0.1935 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0071 | 0.2156 | 0.2057 |
Treponema pallidum | flavodoxin | 0.0054 | 0.0239 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 1 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.0124 | 0.8203 | 0.818 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0054 | 0.0239 | 0.0115 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0054 | 0.0239 | 0.0115 |
Chlamydia trachomatis | sulfite reductase | 0.0087 | 0.3953 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.014 | 1 | 0.5 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0054 | 0.0239 | 0.0115 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.007 | 0.2036 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0054 | 0.0239 | 0.0115 |
Plasmodium vivax | hypothetical protein, conserved | 0.0054 | 0.0239 | 0.0115 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0054 | 0.0239 | 0.0239 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.014 | 1 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0054 | 0.0239 | 0.0115 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.014 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0087 | 0.3953 | 0.3876 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.014 | 1 | 1 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0054 | 0.0239 | 0.0115 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0054 | 0.0239 | 0.0115 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0053 | 0.0125 | 0.0125 |
Trichomonas vaginalis | sulfite reductase, putative | 0.014 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.014 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.014 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.014 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.014 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0124 | 0.8203 | 0.818 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0087 | 0.3953 | 0.3953 |
Giardia lamblia | Hypothetical protein | 0.0124 | 0.8203 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.014 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.014 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.007 | 0.2036 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0053 | 0.0125 | 0.0125 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.014 | 1 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0054 | 0.0239 | 0.0115 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0124 | 0.8203 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0087 | 0.3953 | 0.3876 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0054 | 0.0239 | 1 |
Brugia malayi | flavodoxin family protein | 0.0054 | 0.0239 | 0.0115 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.014 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.014 | 1 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.0054 | 0.0239 | 0.0115 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0124 | 0.8203 | 0.818 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.014 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0053 | 0.0125 | 0.0125 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.03 uM | Inhibition of CDK4/Cyclin D1 assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation | ChEMBL. | 19317452 |
IC50 (functional) | = 6.7 uM | Cytotoxicity against human HCT116 cells after 3 days by SRB assay | ChEMBL. | 19317452 |
IC50 (functional) | = 8.2 uM | Cytotoxicity against human MCF7 cells after 3 days by SRB assay | ChEMBL. | 19317452 |
IC50 (binding) | = 13.6 uM | Inhibition of CDK2/Cyclin E assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation | ChEMBL. | 19317452 |
IC50 (binding) | > 50 uM | Inhibition of CDK1/Cyclin B1 assessed as inhibition of retinoblastoma susceptibility gene product phosphorylation | ChEMBL. | 19317452 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 19317452 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.